Usual Care Intervention Research Evaluating the Impact of a Personalized Pharmaceutical Plan on the Duration of Opioid Treatment in Non-cancerous Pain

Opioid Use Clinical Trial

— PPP-Care  

Official title:

Usual Care Intervention Research Evaluating the Impact of a Personalized Pharmaceutical Plan on the Duration of Opioid Treatment in Non-cancerous Pain

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05196386
• Other study ID #: 2019/025/HP
• Status: Recruiting
• Phase: N/A
• Start date: August 6, 2020
• Est. completion date: March 2023

Study information

• Verified date: January 2022
• Source: University Hospital, Rouen
• Contact: Olivier VITTECOQ, Pr
• Phone: +3323288
• Email: olivier.vittecoq[@]chu-rouen.fr
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Many treatments with WHO grade III opioids are being introduced in the rheumatology department for non-cancerous pain. The duration of this treatment prescribed at discharge is often uncontrolled and sometimes leads to significant addiction.

The team at the local pain center recommends an average duration of 28 days for this type of pain. There is a full-time pharmacy intern in the rheumatology department.

The aim of this work is to evaluate the impact of a targeted pharmaceutical interview on the duration of the morphine treatment initiated during hospitalization.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 100
• Est. completion date: March 2023
• Est. primary completion date: March 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

• Age = 18 and < 75 years old when entering the rheumatology department

• Hospitalization in the rheumatology department

• Patient with acute non-traumatic musculoskeletal disease

• Patient not taking grade III opioid treatment

• Patient affiliated to a social security scheme

• Patient having read and understood the information letter and signed the consent form

• Patient present on a day which the pharmacy intern is present

Exclusion Criteria:

• Presence of cancer, fibromyalgia, already diagnosed at inclusion

• Patient does not understand French

• Patient with Current or past opioid addiction

• Person deprived of liberty by administrative or judicial decision

Related Conditions & MeSH terms

• Opioid Use

Intervention

Behavioral:
• Admission conciliation interview
Previous treatment conciliation at hospital admission
• Discharge conciliation interview
Allocated treatment during hospital stay
• Targeted pharmaceutical interview
Specific information about treatment delivered by pharmacist

Locations

Country	Name	City	State
France	Rouen University Hospital	Rouen

Sponsors (1)

Lead Sponsor	Collaborator
University Hospital, Rouen

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Total duration of opioid treatment		6 months
Secondary	Rate of patients exceeding 28 days of cumulative duration of treatment		6 months
Secondary	Rate of patients exceeding 90 days of cumulative duration of treatment		6 months